Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, van Dam KPJ, Stalman EW, Vogelzang EH, Cristianawati O, Keijzer S, Vidarsson G, Voskuyl AE, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G. Boekel L, et al. Among authors: killestein j. Lancet Rheumatol. 2021 Nov;3(11):e778-e788. doi: 10.1016/S2665-9913(21)00222-8. Epub 2021 Aug 6. Lancet Rheumatol. 2021. PMID: 34396154 Free PMC article.
Differential effect of drug interference in immunogenicity assays.
Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Hart MH, et al. Among authors: killestein j. J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29. J Immunol Methods. 2011. PMID: 21824477
Drug interference in immunogenicity assays depends on valency.
Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D. Rispens T, et al. Among authors: killestein j. J Pharm Biomed Anal. 2013 Nov;85:179-85. doi: 10.1016/j.jpba.2013.07.022. Epub 2013 Jul 30. J Pharm Biomed Anal. 2013. PMID: 23954437
Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.
de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL. de Jong TD, et al. Among authors: killestein j. Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9. Arthritis Res Ther. 2016. PMID: 26882897 Free PMC article.
Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.
van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T. van Schie KA, et al. Among authors: killestein j. J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. J Allergy Clin Immunol. 2017. PMID: 27717666 No abstract available.
309 results